Incisional biopsies of both plaques with immunohistochemistry favoured a CD4<sup>+</sup> reactive lymphoid process in keeping with cutaneous pseudolymphoma (CPL), secondary to pembrolizumab, an immune checkpoint inhibitor (ICI). The gene discussed is CD4; the disease is congenital pulmonary lymphangiectasia.